Key Approaches to Pain Management in Hidradenitis Suppurativa
DOI:
https://doi.org/10.58931/cdt.2025.63148Abstract
Many patients living with hidradenitis suppurativa (HS) experience a significant impairment in their quality of life. One of the most prominent symptoms in these patients is pain, which makes a major contribution to their overall distress. Despite its impact, pain control has been shown to be an unmet need for many patients. Pain has physical, psychological and social impacts. When poorly controlled, pain can lead to increased visits to emergency departments, a higher likelihood of self-medication, and generally poor disease control. This review provides a clinical approach for managing pain in patients with HS.
References
GBE, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366-376. doi:10.1016/j.jaad.2019.06.1301
Orenstein LAV, Salame N, Siira MR, Urbanski M, Flowers NI, Echuri H, et al. Pain experiences among those living with hidradenitis suppurativa: a qualitative study. Br J Dermatol. 2023;188(1):41-51. doi:10.1093/bjd/ljac018
Taylor MT, Orenstein LAV, Barbieri JS. Pain severity and management of hidradenitis suppurativa at US emergency department visits. JAMA Dermatol. 2021;157(1):115-117. doi: 10. 1001/ jama dermatol. 2020. 4494
Sampogna F, Campana I, Fania L, Mastroeni S, Fusari R, Ciccone D, et al. Pain as defining feature of health status and prominent therapeutic target in patients with hidradenitis suppurativa. J Clin Med. 2021;10(16):3648. doi:10.3390/jcm10163648
Savage KT, Singh V, Patel ZS, Yannuzzi CA, McKenzie-Brown AM, Lowes MA, et al. Pain management in hidradenitis suppurativa and a proposed treatment algorithm. J Am Acad Dermatol. 2021;85(1):187-199. doi:10.1016/j.jaad.2020.09.039
Dagenet CB, Lee KH, Fragoso NM, Shi VY. Approach to the patient with hidradenitis suppurativa: evaluating severity to guide therapy. J Am Acad Dermatol. 2024;91(6):S22-S26. doi:10.1016/j.jaad.2024.09.007
Treede R-D, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630-1635. doi:10.1212/01.wnl.0000282763.29778.59
Huilaja L, Hirvonen MJ, Lipitsä T, Vihervaara A, Harvima R, Sintonen H, et al. Patients with hidradenitis suppurativa may suffer from neuropathic pain: a Finnish multicenter study. J Am Acad Dermatol. 2020;82(5):1232-1234. doi:10.1016/j.jaad.2019.11.016
Garcovich S, Muratori S, Moltrasio C, Buscemi AA, Giovanardi G, Malvaso D, et al. Prevalence of neuropathic pain and related characteristics in hidradenitis suppurativa: a cross-sectional study. J Clin Med. 2020;9(12):4046. doi:10.3390/jcm9124046
Aarts P, Aitken JJ, van Straalen KR. Prevalence of central sensitization in patients with hidradenitis suppurativa. [published correction appears in JAMA Dermatol. 2021 Oct 1;157(10):1246. doi: 10.1001/jamadermatol.2021.4420.]. JAMA Dermatol. 2021;157(10):1209-1212. doi:10.1001/jamadermatol.2021.2918
Surapaneni V, Milosavljevic MV, Orenstein LAV. Pain management in hidradenitis suppurativa. J Am Acad Dermatol. 2024;91(6):S52-S63. doi:10.1016/j.jaad.2024.09.006
Schreiber K, Frishman M, Russell MD, Dey M, Flint J, Allen A, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice. Rheumatology (Oxford). 2023;62(4):e89-e104. doi:10.1093/rheumatology/keac552
Ghanshani R, Lee K, Crew AB, Shi VY, Hsiao JL. A Guide to the management of hidradenitis suppurativa in pregnancy and lactation. Am J Clin Dermatol. 2025;26(3):345-360. doi:10.1007/s40257-025-00935-x
Alhusayen R, Dienes S, Lam M, Alavi A, Alikhan A, Aleshin M, et al. North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations. J Am Acad Dermatol. 2025;92(4):825-852. doi:10.1016/j.jaad.2024.11.071
Shanmugam VK, Mulani S, McNish S, Harris S, Buescher T, Amdur R. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy. Int J Dermatol. 2018;57(1):62-69. doi:10.1111/ijd.13798
Bechara FG, Podda M, Prens EP, Horvath B, Giamarellos-Bourboulis EJ, Alavi A, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001-1009. doi:10.1001/jamasurg.2021.3655
Aarts P, van Huijstee JC, van der Zee HH, van Doorn MBA, van Straalen KR, Prens EP. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a Randomized Controlled Trial in a real-world setting. J Am Acad Dermatol. 2023;89(4):677-684. doi:10.1016/j.jaad.2023.04.034
Ravi S, Miles JA, Steele C, Christiansen MK, Sayed CJ. Patient impressions and outcomes after clinic-based hidradenitis suppurativa surgery. JAMA Dermatol. 2022;158(2):132-141. doi:10.1001/jamadermatol.2021.4741
Hayoun M, Misery L. Pain management in dermatology. Dermatology. 2023;239(5):675-684. doi:10.1159/000531758)
PENTHROX® (methoxyflurane). Endo Ventures Ltd. Importer/Distributor: Paladin Labs Inc., St-Laurent, QC: Product Monograph. [Updated April 21, 2022, Accessed May 30, 2025]. Available from: https://pdf.hres.ca/dpd_pm/00065552.PDF
Gamboa J, Cameron MC, Fathi R, Alkousakis T. A review of non-pharmacologic approaches to enhance the patient experience in dermatologic surgery. Dermatol Online J. 2020;26(3):13030/qt7mp372nd. Published 2020 Mar 15
